Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 17/20 | 0.81 |
| ▸ | TACR1 | P25103 | 16/20 | 0.81 |
| ▸ | TACR3 | P29371 | 9/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | CCR5 | P51681 | 2/20 | 0.66 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31224200 | 1.00 | TACR2 (0.81) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL24855387 | 1.00 | TACR2 (0.81) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL7378893 | 0.92 | TACR2 (0.74) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL7307760 | 0.92 | TACR2 (0.79) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL31224303 | 0.92 | TACR2 (0.79) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL24855513 | 0.92 | TACR2 (0.79) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL7309714 | 0.91 | TACR2 (0.78) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL8593237 | 0.91 | TACR2 (0.78) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL7308765 | 0.91 | TACR2 (0.75) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL7309969 | 0.90 | TACR2 (0.74) | TACR2TACR1TACR3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336565-A1 | SOLID FORMS OF OSANETANT | ACER THERAPEUTICS INC. | 2024-10-10 | — | — | US | disclosed |
| EP-0915849-A2 | PROCESS FOR THE PREPARATION OF 3,3-DISUBSTITUTED PIPERIDINES | Smithkline Beecham S.p.A. (IT) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998005640-A2 | PROCESS FOR THE PREPARATION OF 3,3-DISUBSTITUTED PIPERIDINES | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336565-A1 | SOLID FORMS OF OSANETANT | OAT, OPA1, CPS1 | TACR2 1620/4885TACR1 898/4885TACR3 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.